A Synthetic Gene Circuit for Self-Regulating Delivery of Biologic Drugs in Engineered Tissues
AUTHORS
Pferdehirt
LLara ,
Ross
AKAlison K ,
Brunger
JMJonathan M ,
Guilak
FFarshid .
Tissue engineering. Part A. 2019 5 10; 25(9-10).
809-820
- PMID: 30968743[PubMed].
ABSTRACT
IMPACT STATEMENT: We engineered a synthetic transcription system based on nuclear factor kappa-light-chain-enhancer of activated B cells signaling that can attenuate the effects of the inflammatory cytokine interleukin (IL)-1α in a self-regulating manner. This system responds in a time- and dose-dependent manner to rapidly produce therapeutic levels of IL-1 receptor antagonist (IL-1Ra). The use of lentiviral gene therapy allows this system to be utilized through different transduction methods and in different cell types for a variety of applications. Broadly, this approach may be applicable in developing autoregulated biologic systems for tissue engineering and drug delivery in a range of disease applications.